Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor. This marks the first continuous glucose monitor (CGM) integration for twiist. Manchester, New Hampshire-based Sequel expects to launch the combination in the second quarter of 2025. Sequel won FDA clearance for the twiist […]
abbott
Abbott inks first Lingo retail deal with Amazon
Abbott (NYSE:ABT) announced that it made its Lingo continuous glucose monitoring (CGM) system available for purchase on Amazon. The CGM, which utilizes a single sensor for up to 14 days and doesn’t require a prescription, retails for $49 on the popular online marketplace. It also has eligibility on Amazon Prime, where available. Lingo, an over-the-counter […]
Data outlines need for CGM study design guidelines
A study looking at three leading continuous glucose monitors (CGMs), including systems from Abbott and Dexcom, signaled the need for new guidelines, investigators say. Published in the Journal of Diabetes Science and Technology, the study evaluated the latest-generation Abbott FreeStyle Libre 3, Dexcom G7 and Medtronic Simplera CGMs against different comparator methods and during clinically […]
Sinocare prevails in CGM trademark spat with Abbott
Sinocare announced recently that it successfully defended itself in court against trademark infringement claims brought by Abbott (NYSE:ABT). The China-based continuous glucose monitor (CGM) maker defended itself in the High Court of Justice (Chancery Division) of England and Wales against claims regarding trademark infringement and passing off. Abbott claimed that Sinocare’s iCan i3 CGM system […]
Are over-the-counter CGMs on track to be one-hit wonders?
This medical device design expert’s family conducted a group trial of Dexcom Stelo and Abbott Lingo CGMs. By Steph Habif “Did you say you are now wearing a CGM?” my 78-year-old father asked me one day. “If so, what brand do you think is best for me to try?” My dad wanted my opinion because […]
Abbott leader, expert discuss stigma around diabetes management
Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with managing diabetes. With this initiative, the company wants to address misconceptions and stereotypes that weight heavily on the minds of those with diabetes. These can create yet another barrier to care, potentially preventing people […]
Abbott launches initiative to combat diabetes stigma
Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management. The maker of the leading FreeStyle Libre continuous glucose monitor (CGM) platform launched the “Above the Bias” initiative after a new survey highlighted how everyday comments centered around food, appearances and other stigmas may affect people living with diabetes. […]
Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024. The company’s medical device business saw a 13.7% overall increase in sales, with double-digit growth both in the U.S. and abroad. Abbott pointed to a number of products contributing to the performance, including the FreeStyle Libre continuous glucose monitor […]
Abbott, Dexcom settle global CGM patent litigation
Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]
The 5 most-read Drug Delivery Business News stories of 2024
There has been no shortage of news across the diabetes and drug delivery markets over the course of 2024. At Drug Delivery Business News, we’ve tried to cover it all. From product launches to major regulatory nods — with significant partnerships and integrations in between — diabetes technology particularly dominated the news over the last 12 […]
